|Company Name:||ImmunoCellular Therapeutics Ltd|
|Event Title:||Business Update Call Transcript|
|Event Time:||12:00 PM ET|
Good afternoon everyone and welcome to the today's conference call. At this time all lines have being place on a listen-only mode and the floor will be open for your questions and comments following the presentation. [Operator Instructions]. At this time, it is my pleasure to turn the floor to your host of Jeff Ramsen, CEO of proactive capital group. Sir, the floor is yours.
Founder/CEO at ProActive Capital Group
Thank you. My name is Jeff Ramson and I am the CEO of ProActive Capital Group. I would like to welcome you to today's call, which is entitled Glioblastoma - Brain Cancer:The Next Generation of Therapies. We are very fortunate to have a panel today which is comprised of senior management from two companies and associated medical experts, all dedicated to transforming these therapies for brain cancer.
From ImmunoCellular therapeutics we have Dr. John Yu, Chairman and Founder along with Andrew Gengos, CEO.
From Agenus we have Dr. Garo Armen, Chairman and CEO.
Our medical experts are Dr. Andrew Parsa, Michael J. Marchese Professor and Chair, Department of Neurological Surgery at Northwestern University School of Medicine; and Dr. John A. Boockvar, Professor of Neurological Surgery and Co-director of the Brain and Spinal Tumor Program at the Weill Cornell Brain and Spine Center.
Our discussion today is being moderated by the Maxim Group's biotechnology team, comprised of Jason Kolbert, Dr.Echo and Dr. Khan.
At this point, I'd like to turn the conversation to Jason Kolbert.
Managing Director, Biotechnology - Maxim Group
Certainly. Thanks Jeff. I really appreciate that. And thanks everyone for joining us. These are two exciting micro-cap companies and one of the hottest areas in biotechnology today, Cancer Immunotherapy. We cover both companies at Maxim. We really like both stocks and in fact when we look at the details of both companies we think these therapies might actually even be synergistic together.
The opportunity to speak not only with the companies but with respective experts in the fields who have been involved with these therapies was just to good to pass up. So with that said today's goal is to talk with management, understand what these therapies are, understand how they work, understand how the experts view them, what their clinical experience has been and what the next steps that would look forward to with each of the respective companies.
So, at this time let me take a few moments and let me introduce each company.
First, we are going to hear from Andrew Gengos, the CEO of ImmunoCellular, who will introduce not only himself but Dr. John Yu and their key oncology expert Dr. John Boockvar.
President, Chief Executive Officer and Director, ImmunoCellular
Thanks Jason and it's Andrew here. You have heard of Jeff's introduce Boockvar. I will just follow on that by saying he's a board certified neuro surgeon and focuses on treating patients with brain tumor skull based disorders and disorders of the spine. John's recognized for his novel research in brain tumors and stem cell biology. As Dr. Boockvar and Yu our collegues in this field, I will ask John Yu, our Founder to say a few words about Dr. Boockvar as well.